Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vivet Therapeutics
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Spain now enjoys a reasonable level of venture capital to help translate its scientific excellence into budding biotechs and the country's major life sciences backer Ysios is looking to unearth more jewels there, as well as in the rest of Europe and North America.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
UCB has been looking to go deep into the gene therapy space for some time, CSO Dhaval Patel tells Scrip, saying that instead of treating symptoms, "you should be going for a cure."
- Drug Delivery
- Gene Therapy, Cell Therapy